Welcome to our dedicated page for Vita Coco Company SEC filings (Ticker: COCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vita Coco Company, Inc. (NASDAQ: COCO) files reports and disclosures with the U.S. Securities and Exchange Commission as part of its obligations as a public company. This page compiles those SEC filings and pairs them with AI-powered tools that help explain the information contained in key documents.
Through its filings, the company reports on topics such as quarterly and annual financial performance, business developments, and regulatory matters. Recent Form 8-K filings, for example, reference press releases announcing financial results for quarters ended June 30 and September 30, 2025, as well as a company statement regarding tariff relief affecting coconut water products. These filings provide detail on net sales, gross profit, net income, and non-GAAP measures like Adjusted EBITDA, along with management’s commentary on factors such as tariffs, costs, and demand for Vita Coco Coconut Water and related products.
On this page, users can access core documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K as they become available through EDGAR. AI-generated summaries are designed to highlight major themes, clarify technical language, and surface items that may matter to shareholders, such as segment performance, tariff discussions, or capital allocation programs mentioned in earnings releases.
In addition, this page provides convenient access to insider transaction reports on Form 4 and other ownership-related filings when they are filed. Together, these resources allow investors, analysts, and interested readers to review The Vita Coco Company’s regulatory disclosures in one place, with AI assistance to make complex filings easier to understand.
Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported sales of a total of 7,894 shares of common stock on 10/07/2025 under a Rule 10b5-1 trading plan at weighted average prices in the range of approximately $42.51–$42.91. After the transactions the filing reports 287,062 shares beneficially owned directly and 221,131 shares held indirectly through family trusts. The filing also discloses outstanding non-qualified stock options exercisable for 1,099,460 shares in aggregate, with several option grants fully vested and others vesting in scheduled installments through 2035. The sales were effected pursuant to a pre-established plan and the form was signed by an attorney-in-fact on behalf of the reporting person.
Vita Coco Company, Inc. (COCO) reported insider sales by Martin Roper executed under a Rule 10b5-1 trading plan. The filing shows multiple dispositions of 5,000 shares on 10/03/2025 and 10/06/2025, with reported weighted-average prices around $42.6–$42.9. After the reported sales, Mr. Roper directly beneficially owned 293,897 shares and held indirect interests through family trusts and related parties; several family trusts show remaining indirect holdings in the low- to mid-200,000s.
The form also lists fully vested and exercisable non-qualified stock options and other option grants: a large exercisable option for 579,670 shares at an exercise price of $10.178, plus additional option tranches totaling several hundred thousand shares with exercise prices from $10.178 to $32.78 and various vesting/expiration dates through 2035. The sales were made pursuant to a 10b5-1 plan; the filer offered to provide transaction-level price details on request.
Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported multiple sales of company common stock under a Rule 10b5-1 trading plan executed on 10/01/2025 and 10/02/2025. The filings show repeated disposals of 5,000-share blocks at weighted average prices in the low $42 range (reported ranges between $41.79 and $42.66). Following the reported 10/01 sale the filing shows 303,897 shares beneficially owned directly; following the 10/02 sale that direct ownership is shown as 298,897. The Form 4 also discloses multiple indirect holdings by related family trusts and a spouse, and reports several non-qualified stock options with exercise prices from $10.178 to $32.78, some fully vested and currently exercisable and others subject to multi-year vesting schedules.
Insider transactions by Vita Coco Company, Inc. (COCO) show the chief operating officer engaged in a planned sale of 3,173 shares of common stock under a Rule 10b5-1 trading plan at $42.50 per share, which reduced his direct holdings from 79,300 to 76,127 shares. The filing also reports the grant and continued ownership of multiple non-qualified stock options with exercise prices ranging from $10.178 to $33.36, some fully vested and exercisable and others subject to multi-year vesting schedules. The disclosure records routine option grants and an executed plan-based sale, providing transparency about executive equity and compensation.
Verlinvest Beverages SA reported beneficial ownership of 4,097,161 shares of The Vita Coco Company, Inc. (ticker COCO), representing 7.2% of the company's outstanding common stock based on 56,822,981 shares outstanding as of July 28, 2025. The filing is a Schedule 13G/A under the Securities Exchange Act and shows Verlinvest holds sole voting and dispositive power over all reported shares. The report lists Verlinvest's address in Ixelles, Belgium, and cites the issuer's principal executive office in New York. No shared ownership, group affiliations, or parties on whose behalf shares are held are disclosed.
Insider sales by Vita Coco CEO and related trusts. Martin Roper reported multiple Rule 10b5-1 sales of common stock on September 24-25, 2025, disposing of blocks of 5,000 and 400 shares at weighted average prices in the ~$40.00–$41.67 range. After these transactions the reporting person directly held 319,297 shares. Related family trusts and spouses show indirect holdings ranging from 252,515 to 253,931 shares, and an additional 61,200 shares are held by a spouse. The filing also discloses large outstanding stock option positions fully exercisable or vesting across 2022–2026, totaling several hundred thousand underlying shares.
Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported open-market sales of common stock executed under a Rule 10b5-1 trading plan on September 22 and 23, 2025. The filing shows two sales by the reporting person of 5,000 shares on 09/22/2025 and 5,000 shares on 09/23/2025 at weighted-average prices in the ~$40.14–$40.52 range, leaving 324,297 shares held directly after the 09/23 sale. The form also discloses multiple indirect holdings through family trusts and a spouse, and a total of 1,099,460 outstanding stock options across several grant dates and exercise prices, including fully vested options exercisable now.
Michael Kirban, Executive Chairman and Director of Vita Coco Company, Inc. (COCO), reported transactions on 09/22/2025. He sold 20,000 shares of common stock pursuant to a Rule 10b5-1 trading plan at a weighted average price of $41.535 per share. The Form 4 shows he beneficially owns 1,529,049 shares indirectly through the Michael Kirban 2010 Trust and additional holdings reflected as direct and indirect positions. The filing also lists multiple outstanding non-qualified stock options with exercise prices from $10.178 to $32.78 and varying vesting or exercisability dates.
Martin Roper, a director and CEO of Vita Coco Company, Inc. (COCO), amended a Form 4 to report multiple sales of common stock executed pursuant to a Rule 10b5-1 trading plan on September 15–17, 2025. The Form 4/A shows a series of disposals reported as sales (code S) that reduced both direct and indirect beneficial holdings and reports weighted-average prices for the transactions in ranges approximately between $40.00 and $40.54 per share. The filing also discloses several fully vested and unvested non‑qualified stock options exercisable for large blocks of common stock, with exercise prices from $10.178 to $32.78 and various vesting schedules and expiration dates through 2035. The amendment restates the original Form 4 filed September 18, 2025.
Vita Coco insider Form 4: Martin Roper stock sales and option holdings. The filing reports that Martin Roper, CEO and director, sold four blocks of common stock on 09/18/2025 pursuant to a Rule 10b5-1 trading plan, disposing of 5,000 shares in his name and 5,000 shares each tied to three family trusts for a total reported disposals of 20,000 shares at weighted average prices around $40.00–$40.11 per share. The filing also discloses substantial currently exercisable and non-exercisable non-qualified stock options totaling 1,098,460 underlying shares across multiple grants with exercise prices ranging from $10.178 to $32.78.